News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
1,155 Results
Type
Article (61)
Press Release (1094)
Section
Business (255)
Deals (49)
Drug Development (363)
FDA (44)
Job Trends (30)
News (693)
Policy (65)
Tag
Academia (1)
Alliances (57)
Approvals (44)
Automation (1)
Best Places to Work (28)
Clinical research (337)
COVID-19 (5)
Data (2)
Diabetes (3)
Diagnostics (4)
Earnings (135)
Events (184)
Executive appointments (1)
FDA (48)
Gene therapy (1)
GLP-1 (3)
Government (8)
Healthcare (5)
Infectious disease (5)
IPO (27)
Job creations (2)
Layoffs (1)
Legal (4)
Manufacturing (1)
Medical device (7)
Medtech (7)
Mergers & acquisitions (23)
Metabolic disorders (4)
Neuroscience (1)
NextGen: Class of 2025 (5)
Non-profit (1)
Obesity (1)
Parkinson's disease (1)
People (49)
Phase I (50)
Phase II (142)
Phase III (165)
Pipeline (1)
Postmarket research (15)
Preclinical (11)
Radiopharmaceuticals (1)
Real estate (3)
Regulatory (61)
Research institute (2)
Startups (11)
Weight loss (1)
Date
Last 30 days (1)
Last 365 days (24)
2025 (18)
2024 (52)
2023 (56)
2022 (51)
2021 (57)
2020 (74)
2019 (78)
2018 (62)
2017 (83)
2016 (65)
2015 (81)
2014 (60)
2013 (37)
2012 (48)
2011 (49)
2010 (48)
Location
Africa (1)
Asia (54)
Australia (5)
California (7)
Canada (11)
Europe (242)
Florida (1)
Maryland (1)
Massachusetts (7)
Michigan (1)
New Jersey (1)
New York (1)
North Carolina (6)
Northern California (5)
Southern California (1)
United States (25)
1,155 Results for "ttp ventus".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Ventus Therapeutics to Present at 2025 Bloom Burton & Co. Healthcare Investor Conference
April 29, 2025
·
1 min read
Press Releases
Ventus Therapeutics to Present Phase 1 Results for VENT-03, a First-in-Class cGAS Inhibitor, at LUPUS 2025
May 22, 2025
·
4 min read
Press Releases
Ventus Therapeutics Appoints Mona Kotecha, M.D., as Chief Medical Officer
February 19, 2025
·
2 min read
Press Releases
Ventus Therapeutics Announces Publication in Nature’s Communications Chemistry Describing the Structure-based Optimization of a New Series of cGAS Inhibitors
March 26, 2025
·
3 min read
Press Releases
Ventus Therapeutics Announces Nature Reviews Immunology Publication Demonstrating the Promise of Caspase-4/5 as Therapeutic Targets
March 6, 2025
·
4 min read
Genetown
Ventus Therapeutics to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference
Ventus Therapeutics, Inc announced today that its President and Chief Executive Officer, Marcelo Bigal, M.D., Ph.D., will present at the 2024 Bloom Burton & Co. Healthcare Investor Conference.
April 8, 2024
·
2 min read
Business
Cellular Origins, a TTP Company, Appoints Peter Crossley as Chief Operating Officer
Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies, announced the appointment of Peter Crossley as Chief Operating Officer.
January 25, 2024
·
2 min read
Press Releases
Ventus Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating VENT-02, an Oral, Brain-Penetrant NLRP3 Inhibitor, in Parkinson’s Disease
March 10, 2025
·
4 min read
Drug Development
Ventus Therapeutics Announces First Participant Dosed in Clinical Study with an NLRP3 Inhibitor Licensed Exclusively to Novo Nordisk
Ventus Therapeutics, Inc. today announced that its partner, Novo Nordisk, has successfully dosed the first participant in a Phase 1 clinical study for NNC6022-0001 (formerly known as VENT-01).
May 3, 2024
·
6 min read
Drug Development
Ventus Therapeutics Announces Results from Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor
Ventus Therapeutics today announced results from its Phase 1 clinical trial of VENT-02, a novel, oral, brain-penetrant NLRP3 inhibitor.
April 17, 2024
·
7 min read
1 of 116
Next
